Journal of Medical Virology, Journal Year: 2025, Volume and Issue: 97(2)
Published: Jan. 27, 2025
ABSTRACT The biological applications of noncationic porphyrin‐fullerene (P‐F) dyads as anti‐HIV agents have been limited despite the established use several cationic P‐F anti‐cancer photodynamic therapy (PDT) agents. This article explores potential amphiphilic non‐cationic HIV‐1 inhibitors under both PDT (light‐treated) and non‐PDT (dark) conditions. dyads, PB 3 C 60 70 , demonstrated enhanced efficacy in inhibiting entry production (subtypes B C). Under light‐harvested conditions, exhibited potent inhibitory effects (EC 50 for < 10 nM) also maintained significant inhibition conditions = 1.43 μM 1.50 μM), while displaying notably reduced toxicity compared to their water‐soluble porphyrin precursor. substantial neutralizing T20‐resistant strain 9491, at postentry phases, thereby addressing challenge drug resistance.
Language: Английский